Antidepressant Discontinuation Symptoms and Management

Antidepressant discontinuation syndrome is a constellation of physical and psychological symptoms that emerge upon reduction or cessation of therapy. Common manifestations include dizziness, gastrointestinal upset, sensory disturbances often described as “electric shock” sensations, sleep disruption and mood dysregulation such as irritability or heightened anxiety. Although selective serotonin reuptake inhibitors (SSRIs) generally exhibit favourable tolerability, agents with shorter half-lives—paroxetine in particular—are associated with more pronounced withdrawal effects. Emerging mechanistic studies suggest that abrupt cessation may provoke a rebound increase in serotonergic neurotransmission, while residual symptoms can persist for weeks or months, complicating the distinction from relapse of the underlying depressive disorder. Clinical management emphasises patient education, personalised tapering schedules based on pharmacokinetic profiles and, where appropriate, substitution with longer-acting compounds. Supportive measures including psychosocial interventions and close monitoring for mood destabilisation are integral to a withdrawal strategy that seeks to balance minimisation of discomfort with mitigation of relapse risk on a global scale.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Antidepressant Discontinuation Symptoms and Management publication trend

The graph below shows the total number of articles in antidepressant discontinuation symptoms and management across all publications each year (not limited to Nature Index journals).

Technical terms

Discontinuation syndrome: A set of symptoms occurring after dose reduction or cessation of antidepressant therapy, encompassing both physical and psychological effects.

Tapering: The gradual reduction of medication dosage designed to minimise withdrawal symptoms and prevent rebound phenomena.

Rebound phenomenon: A transient overshoot of neuronal or receptor activity following abrupt discontinuation of a drug, often intensifying clinical symptoms.

Withdrawal symptoms: Clinical manifestations—such as dizziness, disturbances of sleep and mood alterations—that appear during the discontinuation phase.

Relapse: The re-emergence of core depressive symptoms, requiring differentiation from withdrawal to inform appropriate management strategies.

References

1. Rebound activation of 5-HT neurons following SSRI discontinuation. Neuropsychopharmacology (2024).
2. Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis. Frontiers in Pharmacology (2024).
3. Selective Serotonin Reuptake Inhibitor Antidepressant Treatment Discontinuation Syndrome: A Review of the Clinical Evidence and the Possible Mechanisms Involved. Frontiers in Pharmacology (2013).
4. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych Advances (2022).